Celastrol inhibits IL-1β-induced inflammation in orbital fibroblasts through the suppression of NF-κB activity

Li,Hong; Yuan,Yifei; Zhang,Yali; He,Qianwen; Xu,Rongjuan; Ge,Fangfang; Wu,Chen

doi:10.3892/mmr.2016.5570

Celastrol inhibits IL-1β-induced inflammation in orbital fibroblasts through the suppression of NF-κB activity

Authors:
- Hong Li
- Yifei Yuan
- Yali Zhang
- Qianwen He
- Rongjuan Xu
- Fangfang Ge
- Chen Wu
View Affiliations

Affiliations: Department of Endocrinology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China, Department of Ophthalmology, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai 200031, P.R. China, Longua Medical School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China
Published online on: July 28, 2016 https://doi.org/10.3892/mmr.2016.5570
Pages: 2799-2806

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Graves' disease is an autoimmune disease of the thyroid gland, which is characterized by hyperthyroidism, diffuse goiter and Graves' ophthalmopathy (GO). Although several therapeutic strategies for the treatment of GO have been developed, the effectiveness and the safety profile of these therapies remain to be fully elucidated. Therefore, examination of novel GO therapies remains an urgent requirement. Celastrol, a triterpenoid isolated from traditional Chinese medicine, is a promising drug for the treatment of various inflammatory and autoimmune diseases. CCK‑8 and apoptosis assays were performed to investigate cytotoxicity of celastrol and effect on apoptosis on orbital fibroblasts. Reverse transcription‑polymerase chain reaction, western blotting and ELISAs were performed to examine the effect of celastrol on interleukin (IL)‑1β‑induced inflammation in orbital fibroblasts from patients with GO. The results demonstrated that celastrol significantly attenuated the expression of IL‑6, IL‑8, cyclooxygenase (COX)‑2 and intercellular adhesion molecule‑1 (ICAM‑1), and inhibited IL‑1β‑induced increases in the expression of IL‑6, IL‑8, ICAM‑1 and COX‑2. The levels of prostaglandin E2 in orbital fibroblasts induced by IL‑1β were also suppressed by celastrol. Further investigation revealed that celastrol suppressed the IL‑1β‑induced inflammatory responses in orbital fibroblasts through inhibiting the activation of nuclear factor (NF)‑κB. Taken together, these results suggested that celastrol attenuated the IL‑1β‑induced pro‑inflammatory pathway in orbital fibroblasts from patients with GO, which was associated with the suppression of NF-κB activation.

View Figures

View References

1	Prabhakar BS, Bahn RS and Smith TJ: Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 24:802–835. 2003. View Article : Google Scholar : PubMed/NCBI
2	Bahn RS: Graves' ophthalmopathy. N Engl J Med. 362:726–738. 2010. View Article : Google Scholar : PubMed/NCBI
3	Garrity JA and Bahn RS: Pathogenesis of graves ophthalmopathy: Implications for prediction, prevention, and treatment. Am J Ophthalmol. 142:147–153. 2006. View Article : Google Scholar : PubMed/NCBI
4	Wiersinga WM and Bartalena L: Epidemiology and prevention of Graves' ophthalmopathy. Thyroid. 12:855–860. 2002. View Article : Google Scholar : PubMed/NCBI
5	Ajjan RA and Weetman AP: New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest. 27:237–245. 2004. View Article : Google Scholar : PubMed/NCBI
6	Kazim M, Goldberg RA and Smith TJ: Insights into the pathogenesis of thyroid-associated orbitopathy: Evolving rationale for therapy. Arch Ophthalmol. 120:380–386. 2002. View Article : Google Scholar : PubMed/NCBI
7	Smith TJ: Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: Potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid. 12:197–203. 2002. View Article : Google Scholar : PubMed/NCBI
8	Lee WM, Paik JS, Cho WK, Oh EH, Lee SB and Yang SW: Rapamycin enhances TNF-α-induced secretion of IL-6 and IL-8 through suppressing PDCD4 degradation in orbital fibroblasts. Curr Eye Res. 38:699–706. 2013. View Article : Google Scholar : PubMed/NCBI
9	Yoon JS, Chae MK, Lee SY and Lee EJ: Anti-inflammatory effect of quercetin in a whole orbital tissue culture of Graves' orbitopathy. Br J Ophthalmol. 96:1117–1121. 2012. View Article : Google Scholar : PubMed/NCBI
10	Heufelder AE and Bahn RS: Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy. Clin Exp Immunol. 91:381–389. 1993. View Article : Google Scholar : PubMed/NCBI
11	Kahaly G, Hansen C, Felke B and Dienes HP: Immunohistochemical staining of retrobulbar adipose tissue in Graves' ophthalmopathy. Clin Immunol Immunopathol. 73:53–62. 1994. View Article : Google Scholar : PubMed/NCBI
12	Konuk EB, Konuk O, Misirlioglu M, Menevse A and Unal M: Expression of cyclooxygenase-2 in orbital fibroadipose connective tissues of Graves' ophthalmopathy patients. Eur J Endocrinol. 155:681–685. 2006. View Article : Google Scholar : PubMed/NCBI
13	Wang HS, Cao HJ, Winn VD, Rezanka LJ, Frobert Y, Evans CH, Sciaky D, Young DA and Smith TJ: Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. J Biol Chem. 271:22718–22728. 1996. View Article : Google Scholar : PubMed/NCBI
14	Bartalena L, Pinchera A and Marcocci C: Management of Graves' ophthalmopathy: Reality and perspectives. Endocr Rev. 21:168–199. 2000.PubMed/NCBI
15	Kannaiyan R, Shanmugam MK and Sethi G: Molecular targets of celastrol derived from Thunder of God Vine: Potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 303:9–20. 2011. View Article : Google Scholar
16	Salminen A, Lehtonen M, Paimela T and Kaarniranta K: Celastrol: Molecular targets of Thunder God Vine. Biochem Biophys Res Commun. 394:439–442. 2010. View Article : Google Scholar : PubMed/NCBI
17	Cascão R, Vidal B, Raquel H, Neves-Costa A, Figueiredo N, Gupta V, Fonseca JE and Moita LF: Effective treatment of rat adjuvant-induced arthritis by celastrol. Autoimmun Rev. 11:856–862. 2012. View Article : Google Scholar : PubMed/NCBI
18	Li H, Zhang YY, Tan HW, Jia YF and Li D: Therapeutic effect of tripterine on adjuvant arthritis in rats. J Ethnopharmacol. 118:479–484. 2008. View Article : Google Scholar : PubMed/NCBI
19	Kim DY, Park JW, Jeoung D and Ro JY: Celastrol suppresses allergen-induced airway inflammation in a mouse allergic asthma model. Eur J Pharmacol. 612:98–105. 2009. View Article : Google Scholar : PubMed/NCBI
20	Li H, Zhang YY, Huang XY, Sun YN, Jia YF and Li D: Beneficial effect of tripterine on systemic lupus erythematosus induced by active chromatin in BALB/c mice. Eur J Pharmacol. 512:231–237. 2005. View Article : Google Scholar : PubMed/NCBI
21	Kim DH, Shin EK, Kim YH, Lee BW, Jun JG, Park JH and Kim JK: Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. Eur J Clin Invest. 39:819–827. 2009. View Article : Google Scholar : PubMed/NCBI
22	Sen T, Dutta A and Chatterjee A: Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFkappaB and AP-1 in the human breast cancer cell line MDA-MB-231. Anticancer Drugs. 21:632–644. 2010. View Article : Google Scholar : PubMed/NCBI
23	Ghosh S, May MJ and Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 16:225–260. 1998. View Article : Google Scholar : PubMed/NCBI
24	Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS and Lee JJ: Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol. 72:1311–1321. 2006. View Article : Google Scholar : PubMed/NCBI
25	Sethi G, Ahn KS, Pandey MK and Aggarwal BB: Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood. 109:2727–2735. 2007.
26	Yiu WH, Wong DW, Chan LY, Leung JC, Chan KW, Lan HY, Lai KN and Tang SC: Tissue kallikrein mediates pro-inflammatory pathways and activation of protease-activated receptor-4 in proximal tubular epithelial cells. PLoS One. 9:e888942014. View Article : Google Scholar : PubMed/NCBI
27	Liang C, Du W, Dong Q, Liu X, Li W, Wang Y and Gao G: Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves' disease. Exp Ther Med. 9:925–930. 2015.PubMed/NCBI
28	Zhao LQ, Wei RL, Cheng JW, Cai JP and Li Y: The expression of intercellular adhesion molecule-1 induced by CD40-CD40 L ligand signaling in orbital fibroblasts in patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci. 51:4652–4660. 2010. View Article : Google Scholar : PubMed/NCBI
29	Choi YH, Back KO, Kim HJ, Lee SY and Kook KH: Pirfenidone attenuates IL-1β-induced COX-2 and PGE2 production in orbital fibroblasts through suppression of NF-κB activity. Exp Eye Res. 113:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
31	Chen LF and Greene WC: Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol. 5:392–401. 2004. View Article : Google Scholar : PubMed/NCBI
32	Yoon JS, Lee HJ, Choi SH, Chang EJ, Lee SY and Lee EJ: Quercetin inhibits IL-1β-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves' orbitopathy. PLoS One. 6:e262612011. View Article : Google Scholar
33	Smith TJ: Unique properties of orbital connective tissue underlie its involvement in Graves' disease. Minerva Endocrinol. 28:213–222. 2003.PubMed/NCBI
34	Smith TJ: Novel aspects of orbital fibroblast pathology. J Endocrinol Invest. 27:246–253. 2004. View Article : Google Scholar : PubMed/NCBI
35	Smith RS, Smith TJ, Blieden TM and Phipps RP: Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol. 151:317–322. 1997.PubMed/NCBI
36	Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP and Smith TJ: Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 273:29615–29625. 1998. View Article : Google Scholar : PubMed/NCBI
37	Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM and Prummel MF: TSH-R expression and cytokine profile in orbital tissue of active vs. Inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf). 58:280–287. 2003. View Article : Google Scholar
38	Chen B, Tsui S and Smith TJ: IL-1 beta induces IL-6 expression in human orbital fibroblasts: Identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol. 175:1310–1319. 2005. View Article : Google Scholar : PubMed/NCBI
39	Hwang CJ, Afifiyan N, Sand D, Naik V, Said J, Pollock SJ, Chen B, Phipps RP, Goldberg RA, Smith TJ and Douglas RS: Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8 and MCP-1. Invest Ophthalmol Vis Sci. 50:2262–2268. 2009. View Article : Google Scholar : PubMed/NCBI
40	Kaback LA and Smith TJ: Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: Potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 84:4079–4084. 1999.PubMed/NCBI
41	Sikorski EE, Hallmann R, Berg EL and Butcher EC: The Peyer's patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumor necrosis factor-alpha and IL-1. J Immunol. 151:5239–5250. 1993.PubMed/NCBI
42	Lie PP, Cheng CY and Mruk DD: The biology of interleukin-1: Emerging concepts in the regulation of the actin cytoskeleton and cell junction dynamics. Cell Mol Life Sci. 69:487–500. 2012. View Article : Google Scholar :
43	Tak PP and Firestein GS: NF-kappaB: A key role in inflammatory diseases. J Clin Invest. 107:7–11. 2001. View Article : Google Scholar : PubMed/NCBI
44	Kiaei M, Kipiani K, Petri S, Chen J, Calingasan NY and Beal MF: Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neuro-degener Dis. 2:246–254. 2005. View Article : Google Scholar
45	He D, Xu Q, Yan M, Zhang P, Zhou X, Zhang Z, Duan W, Zhong L, Ye D and Chen W: The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer. 9:3432009. View Article : Google Scholar :
46	Zhou LL, Lin ZX, Fung KP, Cheng CH, Che CT, Zhao M, Wu SH and Zuo Z: Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-κB activity. Eur J Pharmacol. 670:399–408. 2011. View Article : Google Scholar : PubMed/NCBI